NASDAQ:VIRX Viracta Therapeutics (VIRX) Stock Price, News & Analysis → How Biden has already won 2024 (From Porter & Company) (Ad) Free VIRX Stock Alerts $0.62 -0.02 (-2.98%) (As of 06/7/2024 08:52 PM ET) Add Compare Share Share Today's Range$0.58▼$0.6650-Day Range$0.50▼$1.1752-Week Range$0.43▼$1.77Volume100,800 shsAverage Volume102,917 shsMarket Capitalization$24.19 millionP/E RatioN/ADividend YieldN/APrice Target$6.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Viracta Therapeutics alerts: Email Address Viracta Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside955.2% Upside$6.50 Price TargetShort InterestHealthy2.42% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.21) to ($1.19) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.27 out of 5 starsMedical Sector701st out of 903 stocksPharmaceutical Preparations Industry326th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingViracta Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageViracta Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Viracta Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.42% of the float of Viracta Therapeutics has been sold short.Short Interest Ratio / Days to CoverViracta Therapeutics has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Viracta Therapeutics has recently decreased by 4.43%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldViracta Therapeutics does not currently pay a dividend.Dividend GrowthViracta Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VIRX. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows6 people have added Viracta Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Viracta Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders10.69% of the stock of Viracta Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 31.37% of the stock of Viracta Therapeutics is held by institutions.Read more about Viracta Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Viracta Therapeutics are expected to grow in the coming year, from ($1.21) to ($1.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Viracta Therapeutics is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Viracta Therapeutics is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioViracta Therapeutics has a P/B Ratio of 1.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Viracta Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Market Moving TrendsTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Click to View The 5 Best AI Stocks to Invest In About Viracta Therapeutics Stock (NASDAQ:VIRX)Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.Read More VIRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VIRX Stock News HeadlinesMay 23, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Viracta Therapeutics (VIRX)May 18, 2024 | finanznachrichten.deViracta Therapeutics, Inc.: Viracta Therapeutics Announces New Employment Inducement GrantsMay 17, 2024 | globenewswire.comViracta Therapeutics Announces New Employment Inducement GrantsMay 14, 2024 | globenewswire.comViracta Therapeutics Appoints Michael Faerm as Chief Financial OfficerMay 10, 2024 | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on Viracta Therapeutics (VIRX)May 10, 2024 | investorplace.comVIRX Stock Earnings: Viracta Therapeutics Beats EPS for Q1 2024May 9, 2024 | globenewswire.comViracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 7, 2024 | globenewswire.comViracta Therapeutics to Present at the RBC Capital Markets Global Healthcare ConferenceApril 23, 2024 | msn.comDay One wins FDA nod for brain cancer therapy, OjemdaApril 18, 2024 | markets.businessinsider.comPromising Clinical Trial Results Reinforce Buy Rating for Viracta TherapeuticsApril 17, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Viracta Therapeutics (VIRX) and UnitedHealth (UNH)April 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Icecure Medical (ICCM), Viracta Therapeutics (VIRX) and Bioxcel Therapeutics (BTAI)April 15, 2024 | msn.comWhy Is Small-Cap Cancer Drug Developer Viracta Therapeutics Stock Trading Lower On Monday?April 15, 2024 | globenewswire.comViracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell LymphomaApril 1, 2024 | globenewswire.comViracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of TaiwanMarch 22, 2024 | investing.comViracta Therapeutics CFO and COO Dan Chevallard resignsMarch 12, 2024 | markets.businessinsider.comBuy Rating for Viracta Therapeutics Backed by Upcoming Catalysts and Solid FinancialsMarch 8, 2024 | msn.comVIRX Stock Earnings: Viracta Therapeutics Misses EPS for Q4 2023March 7, 2024 | globenewswire.comViracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 29, 2024 | globenewswire.comViracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 TrialFebruary 17, 2024 | finance.yahoo.comVIRX Mar 2024 2.500 callFebruary 6, 2024 | finance.yahoo.comViracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceJanuary 4, 2024 | finance.yahoo.comViracta Therapeutics Provides Clinical Update and Outlook for 2024December 22, 2023 | benzinga.comViracta Therapeutics Stock (NASDAQ:VIRX) Dividends: History, Yield and DatesDecember 12, 2023 | msn.comViracta gets orphan drug status for Nana-val for EBV tumorsSee More Headlines Receive VIRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viracta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/10/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VIRX CUSIPN/A CIK1061027 Webwww.viracta.com Phone(858) 400-8470Fax650-266-3501Employees40Year FoundedN/APrice Target and Rating Average Stock Price Target$6.50 High Stock Price Target$11.00 Low Stock Price Target$4.00 Potential Upside/Downside+955.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,060,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-244.68% Return on Assets-79.47% Debt Debt-to-Equity RatioN/A Current Ratio1.35 Quick Ratio1.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.33 per share Price / Book1.87Miscellaneous Outstanding Shares39,270,000Free Float35,074,000Market Cap$24.19 million OptionableOptionable Beta0.74 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Mark Andrew Rothera (Age 61)CEO, President & Director Comp: $365.03kDr. Susan Perrine M.D.Scientific Founder and ConsultantDr. Ronald J. Berenson M.D. (Age 72)Co-Founder and Consultant Mr. George HillmanCo-FounderDr. Thalia Papayannopoulou M.D.Co-FounderDr. Robert M. Williams Ph.D. (Age 69)Co-Founder Dr. Douglas V. Faller M.D.Ph.D., Scientific Founder & Chairman of Scientific Advisory BoardMs. Melody Burcar CPA (Age 41)M.B.A., Senior VP of Finance, Interim Principal Financial Officer & Interim Principal Accounting Officer Dr. Ayman El-GuindyChief Scientific OfficerMr. Stewart M. BrownSenior VP of Legal Affairs & General CounselMore ExecutivesKey CompetitorsAssertioNASDAQ:ASRTConnect BiopharmaNASDAQ:CNTBHillstream BioPharmaNASDAQ:HILSRelmada TherapeuticsNASDAQ:RLMDPMV PharmaceuticalsNASDAQ:PMVPView All CompetitorsInsidersDaniel R ChevallardSold 3,405 sharesTotal: $2,485.65 ($0.73/share)Mark RotheraBought 52,094 shares on 11/30/2023Total: $25,526.06 ($0.49/share)Daniel R ChevallardSold 3,720 sharesTotal: $1,860.00 ($0.50/share)Daniel R ChevallardSold 3,512 sharesTotal: $5,092.40 ($1.45/share)View All Insider Transactions VIRX Stock Analysis - Frequently Asked Questions Should I buy or sell Viracta Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Viracta Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VIRX shares. View VIRX analyst ratings or view top-rated stocks. What is Viracta Therapeutics' stock price target for 2024? 4 Wall Street research analysts have issued twelve-month target prices for Viracta Therapeutics' stock. Their VIRX share price targets range from $4.00 to $11.00. On average, they expect the company's stock price to reach $6.50 in the next twelve months. This suggests a possible upside of 955.2% from the stock's current price. View analysts price targets for VIRX or view top-rated stocks among Wall Street analysts. How have VIRX shares performed in 2024? Viracta Therapeutics' stock was trading at $0.57 at the start of the year. Since then, VIRX stock has increased by 8.1% and is now trading at $0.6160. View the best growth stocks for 2024 here. When is Viracta Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our VIRX earnings forecast. How were Viracta Therapeutics' earnings last quarter? Viracta Therapeutics, Inc. (NASDAQ:VIRX) announced its earnings results on Thursday, May, 9th. The company reported ($0.23) earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.12. How do I buy shares of Viracta Therapeutics? Shares of VIRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VIRX) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | SponsoredBuy this small stock before coming AI Tidal WaveThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of ne...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viracta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viracta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.